The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letter to the EditorFull Access

Dr. Centorrino Replies

To the Editor: We agree that polypharmacy, including treatment with multiple psychotropic medications not limited to antipsychotics, is a major concern in the field of psychiatry today and one that warrants both consideration and further study. While our focus in our article was primarily on the use of antipsychotic medication, we are writing a second report using the same subject group that examines combination therapy in particular and includes information on combination psychotropic medication in general. The results presented in this report will highlight the increasing prevalence of combination therapy and compare the possible effects of combination versus monotherapy in factors such as length of inpatient stay, clinical status, and side effects. We maintain, however, that further study into the use and outcome of polypharmacy is necessary.